Currently, FOLFOX (infusional 5-fluorouracil, oxaliplatin, and leucovorin), FOLFIRI (infusional 5-fluorouracil, leucovorin, and irinotecan), or CAPOX (infusional capecitabine and oxaliplatin) combined with various monoclonal antibodies against the vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) are standard CTx regimens for patients with CRC and CRLM [1,15,16,17]. This evidence concerns the gene VEGFA and colorectal carcinoma.